Abstract
Aims
To elucidate the association between baseline renal characteristics and the disparities in renal outcomes among patients with SGLT2i treatment.
Methods
Pubmed, Medline, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrial.gov were searched from inception to November 2022. Event-driven randomized controlled trials of SGLT2i with reports of renal outcomes were included. Sensitivity analyses of prespecified eGFR and UACR subgroups were conducted.
Results
Generally, compared with placebo, the use of SGLT2i was associated with improved renal prognosis (HR = 0.64, 95%CI 0.59–0.70). The magnitude of risk reductions in composite renal outcomes between SGLT2i versus placebo was comparable among different eGFR stratifications (normal renal function: HR = 0.49, 95%CI 0.31–0.79; mild renal impairment: HR = 0.57, 95%CI 0.48–0.68; moderate renal impairment: HR = 0.70, 95%CI 0.63–0.78; severe renal impairment: HR = 0.72, 95%CI 0.62–0.84; P for subgroup difference = 0.09). However, renal benefits seemd to be more prominent in normal to mildly increased albuminuria stratum (HR = 0.51, 95%CI 0.39–0.66) and severely increased albuminuria stratum (HR = 0.57, 95%CI 0.47–0.68), when compared with moderately increased albuminuria stratum (HR = 0.79, 95%CI 0.65–0.96; P for subgroup difference = 0.01).
Conclusions
Generally, the use of SGLT2i was consistently associated with decreased risk of renal events in all prespecified eGFR and albuminuria spectrums, even in patients with substantial renal impairment. The renal benefits of SGLT2i seemed to be independent of baseline eGFR, while the risk reduction in renal events was more profound among patients with mildly increased albuminuria or severely increased albuminuria.
Similar content being viewed by others
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information. No more additional data are available.
References
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306
Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39
Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845–854
Scheen AJ (2020) Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(10):556–577
Neuen BL, Ohkuma T, Neal B et al (2019) Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol 30(11):2229–2242
Mosenzon O, Wiviott SD, Cahn A et al (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7(8):606–617
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128
Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334
Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425–1435
Cherney DZI, Charbonnel B, Cosentino F et al (2021) Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 64(6):1256–1267
Bakris G, Oshima M, Mahaffey KW et al (2020) Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol 15(12):1705–1714
Chertow GM, Vart P, Jongs N et al (2021) Effects of Dapagliflozin in Stage 4 chronic kidney disease. J Am Soc Nephrol 32(9):2352–2361
Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129–139
Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424
Zannad F, Ferreira JP, Pocock SJ et al (2021) Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced. Circulation 143(4):310–321
Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461
Anders HJ, Huber TB, Isermann B et al (2018) CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 14(6):361–377
Alicic RZ, Neumiller JJ, Johnson EJ et al (2019) Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes 68(2):248–257
Cherney D, Lund SS, Perkins BA et al (2016) The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59(9):1860–1870
Kim NH, Kim NH (2022) Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J 46(4):543–551
Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597
Delanaye P, Wissing KM, Scheen AJ (2021) Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. Clin Kidney J 14(12):2463–2471
Webster AC, Nagler EV, Morton RL et al (2017) Chronic kidney disease. Lancet 389(10075):1238–1252
Ye N, Jardine MJ, Oshima M et al (2021) Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation 143(18):1735–1749
Dekkers CCJ, Petrykiv S, Laverman GD et al (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20(8):1988–1993
Ishibashi Y, Matsui T, Yamagishi S (2016) Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 48(3):191–195
Kojima N, Williams JM, Takahashi T et al (2013) Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345(3):464–472
Packer M, Butler J, Zannad F et al (2021) Empagliflozin and major renal outcomes in heart failure. N Engl J Med 385(16):1531–1533
Hu S, Lin C, Cai X et al (2021) The urinary glucose excretion by sodium-glucose cotransporter 2 inhibitor in patients with different levels of renal function: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 12:814074
Lin C, Cai X, Ji L (2022) Cardiovascular benefits beyond urinary glucose excretion: a hypothesis generated from two meta-analyses. Diabetes Obes Metab 24(3):550–554
de Boer IH, Khunti K, Sadusky T et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075–3090
Acknowledgements
We thank the doctors, nurses and technicians for their practical during the study at Department of Endocrinology and Metabolism in Peking University People’s Hospital.
Funding
This work was supported by Bei**g Natural Science Foundation (No. 7202216) and National Natural Science Foundation of China (No. 81970698 and No. 81970708). The funding agencies had no roles in the study design, data collection or analysis, decision to publish or preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
LJ and XC conceptualized this study and designed the systematic review protocol; YM and CL performed the study selection and data extraction; XZ and SH checked the data for accuracy; FL provided with consultation for disagreement; YM, CL and XC performed the statistical analyses; YM, CL and XC prepared the outlines and wrote the manuscript. All authors contributed to the critical revision of manuscript drafts.
Corresponding authors
Ethics declarations
Conflict of interest
LJ has received fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly, Roche, Sanofi-Aventis and Takeda. No other support from any organization for the submitted work other than that described above.
Ethical approval
Since it is a meta-analysis, ethical approval is not applicable.
Ethical Standard Statement
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent disclosure
Since it was a meta-analysis of randomized controlled trials, the informed consents were obtained from the participants before the enrollments of the clinical trials. No further informed consents were required for this meta-analysis.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article belongs to the topical collection Diabetic Nephropathy, managed by Giuseppe Pugliese.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ma, Y., Lin, C., Cai, X. et al. Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis. Acta Diabetol 60, 435–445 (2023). https://doi.org/10.1007/s00592-022-02022-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-022-02022-7